Last updated 2026-06-18
- Went public (NRSN), Dec 2021
- Raised $5M funding round, Dec 2024
- Public offering of $4.5M, Jun 2023
Total raised
$24.2M
Last: 2025-09
Stage
Public
Founded
2017
Headcount
32
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
NeuroSense Therapeutics is a drug development company offering a treatment for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The companys drug, PrimeC, is a unique formulation combining two FDA-approved compounds for unrelated conditions. The company was granted an orphan drug designation by the FDA and the EMA for the use of PrimeC in ALS patients. NeuroSense Therapeutics is currently running two clinical trials in patients with ALS, in Israel and the United States.
Funding history · 5 rounds · $24.2M total
2025-09
$500K
2024-12
$5.0M
2020-04
$120K
2020-02
$580K
2019-08
$1.5M
Q&A
- What is NeuroSense Therapeutics' primary focus?
- NeuroSense Therapeutics is a drug development company focused on creating treatments for patients with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Their lead drug, PrimeC, is a unique formulation of two FDA-approved compounds.
- When did NeuroSense Therapeutics go public on NASDAQ?
- NeuroSense Therapeutics became public on NASDAQ in December 2021.
- What was the total amount raised by NeuroSense Therapeutics through funding rounds?
- NeuroSense Therapeutics has raised a total of $24.2 million USD through funding rounds.
- What was the amount of NeuroSense Therapeutics' most recent public offering?
- In June 2023, NeuroSense Therapeutics had a public offering of $4.5 million USD on NASDAQ.
- What is the employee count for NeuroSense Therapeutics?
- NeuroSense Therapeutics has an employee count in the 11-50 range.
- What is the current market capitalization of NeuroSense Therapeutics?
- NeuroSense Therapeutics has a market capitalization of $22,838,776 USD.
- What is the status of NeuroSense Therapeutics' drug PrimeC for ALS?
- PrimeC has been granted orphan drug designation by both the FDA and the EMA for use in ALS patients. NeuroSense Therapeutics is currently running two clinical trials for PrimeC in ALS patients in Israel and the United States.
- Who is the Co-founder and CEO of NeuroSense Therapeutics?
- Alon Ben-Noon is the Co-founder and CEO of NeuroSense Therapeutics.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
1 PatentsVerified
Tags
pharmaceuticalsamyotrophic-lateral-sclerosis-alsdrug-discoverypharma-companiesneurosciencebiotechnologydegenerative-diseasesrare-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neurosense-tx.com |
|---|---|
| linkedin.com/company/10678539 | |
| facebook.com/neurosensetx | |
| YouTube | youtube.com/channel/UCJU0wswap4MfNS--SCN6s_Q |
Identifiers & details
| Founded | 2017-2 |
|---|---|
| Employees (exact) | 32 |
| Market cap | $22.8M |
| Status reason | Public on NASDAQ on Dec, 2021; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2023-06 | NRSN | $4.5M | ||
| 2021-12 | NRSN | $12.0M |